logo
Plus   Neg
Share
Email

Roche: Port Delivery System With Ranibizumab Shows Positive Trial Results In NAMD

Swiss drug maker Roche (RHHBY) announced Wednesday positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab in people living with neovascular or "wet" age-related macular degeneration or nAMD.

Port Delivery System with ranibizumab or PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customised formulation of ranibizumab over a period of months.

The company noted that the Archway trial met its primary endpoint, demonstrating that patients with PDS who received refills every six months achieved visual acuity outcomes equivalent to those receiving monthly ranibizumab 0.5 mg injections.

In Archway, PDS was generally well-tolerated with a favorable benefit-risk profile.

Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said, "For people around the world receiving frequent eye injections for neovascular AMD, this continuous delivery system could greatly reduce their treatment burden."

The company expects to present detailed Archway results at an upcoming medical meeting and to submit to regulatory authorities across the world.

The Portal study is also investigating the long-term safety and tolerability of PDS for the treatment of nAMD. PDS is also being studied in the Pagoda trial for the treatment of diabetic macular edema or DME, a vision-threatening complication of diabetes.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT